TIC10 is primarily investigated for its potential in cancer therapy due to its ability to activate tumor suppressor pathways. It works by inducing the expression of TRAIL (TNF-related apoptosis-inducing ligand), which promotes apoptosis in cancer cells while sparing normal cells. This selective action makes it a promising candidate for treating various cancers, including colorectal, breast, and pancreatic cancers. Additionally, TIC10 has shown efficacy in overcoming drug resistance in certain cancer types, enhancing its therapeutic value. Research is ongoing to optimize its delivery and efficacy in clinical settings.